HBsAg Seroclearance in Chronic Hepatitis B
Authors:
- Young Sun LeeYLYoung Sun Lee
- Hyun Jung LeeHLHyun Jung Lee
- Eileen YoonEYEileen Yoon
- Young Kul JungYJYoung Kul Jung
- Eun Suck JongEJEun Suck Jong
- Beom Jae LeeBLBeom Jae Lee
- Yeon Seok SeoYSYeon Seok Seo
- Hyung Joon YimHYHyung Joon Yim
- Jong Eun YeonJYJong Eun Yeon
- Jong-Jae ParkJPJong-Jae Park
- Jae Seon KimJKJae Seon Kim
- 1 January 2011
- journal article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 45 (1) , 64-68
Abstract
The long-term clinical course, including the development of hepatocellular carcinoma (HCC) after hepatic B surface antigen (HBsAg) seroclearance is not established. We discovered that the incidence of HCC and the risk factors for HCC in chronic hepatitis B (CHB) patients after HBsAg seroclearance. During 28 years, 96 CHB patients with HBsAg seroclearance were retrospectively reviewed. These patients continued to undergo HCC surveillance. The median follow-up time from initial visit was 166.5 months (range, 7 to 321 mo). The mean age at the initial visit and at the time of seroclearance was 39.2 ± 10.6 years and 46.4 ± 9.9 years, respectively. The mean age at the time of HBsAg seroclearance was significantly lower (P=0.03) in patients with spontaneous HBsAg seroclearance than patients with treatment-associated HBsAg seroclearance. During a median of 56 months (range, 7 to 238 mo) of follow-up after HBsAg seroclearance, 6 (6.5%) patients developed HCC. The mean age at the time of developing HCC was 55.8 ± 10.3 years. On univariate analysis, the evidence of liver cirrhosis from the time of HBsAg seroclearance and age more than 45 years at the time of HBsAg seroclearance were significant risk factors for HCC development. In multivariate analysis, the evidence of liver cirrhosis at HBsAg seroclearance was the only significant risk factor for HCC development. HCC can develop after HBsAg seroclearance in patients with known cirrhosis. Patients who achieved HBsAg seroclearance at older age (>45) may have undiagnosed cirrhosis and hence remain at risk for HCC. HCC surveillance should be carried out for both of those patient populations.Keywords
This publication has 27 references indexed in Scilit:
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment ResponseClinical Gastroenterology and Hepatology, 2007
- Chronic hepatitis BHepatology, 2007
- Delayed Clearance of Serum HBsAg in Compensated Cirrhosis B: Relation to Interferon Alpha Therapy and Disease PrognosisAmerican Journal of Gastroenterology, 1998
- Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfectionJournal of Gastroenterology, 1996
- Spontaneous loss of HBsAg in children with chronic hepatitis B virus infectionHepatology, 1992
- Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective studyHepatology, 1991
- Hepatitis B–Related SequelaeArchives of internal medicine (1960), 1990
- Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinomaJournal of Hepatology, 1987
- The Liver Histology and Frequency of Clearance of the Hepatitis B Surface Antigen (HBsAg) in Chronic CarriersThe American Journal of the Medical Sciences, 1979